Four commercially available non-particulate antacid preparations were titrated against IM hydrochloric acid to assess buffering capacity as compared to 30 1711 O.3M sodium citrate solution. All antacids were used in the manufacturers "unit dose': All antacids tested demonstrated some in vitro buffering capacity, and "Eno" (Reckitt and Colman) had a buffering capacity similar to that of sodium citrate. The retail cost per unit dose was established for each proprietary antacid and for sodium citrate. It was concluded that while proprietary antacids are cheaper per dose than sodium citrate, preparations differ in their acid-neutralising capacity.
Antacid therapy is used to elevate gastric pH as prophylaxis against acid aspiration syndrome. Sodium citrate 0.3M 30 ml is a commonly used antacid because of its non-particulate nature and ability to elevate gastric pH above 2.5 in the majority of cases. I Problems with this agent include its relatively short shelf-life, poor palatability and cost. 2 Several non-particulate antacids have been investigated as potential alternatives to sodium citrate. These include "Alka Seltzer Effervescent",2 soluble paracetamoP and sodium bicarbonate solution: all of which have been identified as having potentially useful buffering capacities.
This study compares the in vitro buffering capacities of four proprietary antacids with that of 0.3M sodium citrate 30 ml using a titration method similar to that described by Murrell and Rosen.' In addition the retail cost per unit dose was calculated for each proprietary antacid and for sodium citrate to determine whether any proprietary antacids might offer a cost-effective alternative to sodium citrate.
MATERIALS AND METHODS
Four proprietary antacids were selected as suitable for testing on the basis of composition. These were: "Ural" (Abbot Laboratories), "Citravescent" (Pacific Pharmaceuticals), "Eno" (Reckitt and Colman Pharmaceuticals) and "Andrews" (Sterling Pharma- Accepted for publication on December I. 1993. ceuticals). Prior testing confirmed that each antacid powder would dissolve in 30 ml water and that each was effervescent. The amount used was the manufacturer's "unit dose". This was one sachet of Ural and Citravescent (4 g) or one teaspoonful of a specific mass (5 or 7 g) for Eno and Andrews. This dose size was chosen for convenience and potential ease of use in the clinical situation.
Comparison was made with 30 ml 0.3M sodium citrate in a commercial sachet ("Sodium Citrate Mixture 8.8070", Delta West Ltd) containing sodium citrate BP with sucrose and methylhydroxybenzoate as additives. This preparation was in clinical use at the time of the study.
Each dose of proprietary antacid was dissolved in 30 ml distilled water. Initial efferverscence was allowed to subside and a control pH measurement was made. Hydrochloric acid IM was added to the antacid from a burette in 2 ml aliquots during continuous stirring. pH measurements were recorded once the pH value was stable. Titration was continued until a total of 30 ml acid had been added. Sodium citrate 0.3M 30 ml from the sachet was titrated against acid in the same manner. A control titration was also performed by titrating acid against 30 ml distilled water.
All pH measurements were made with a Beckmann pH meter calibrated according to manufacturer's instructions and recalibrated after each two titrations. Each antacid preparation was titrated against acid three times. The pH value at each volume of acid added was averaged over three titrations for each antacid. These mean pH values were plotted against volume of acid added to give a titration curve.
Prices for all antacids used in the study were obtained from local retail pharmaceutical outlets, and are "over the counter" prices.
RESULTS
Details of the main active ingredients of each antacid preparation, unit dose size and unit dose costs are given in Table 1 . All proprietary antacids consisted of sodium bicarbonate and citric acid with the variable addition of tartaric acid and sodium citrate. "Andrews" contains a significant quantity of magnesium sulphate for its purgative action. The cost of a 30 ml dose of sodium citrate was markedly higher than unit doses of the proprietary antacids. Titration curves for each antacid are shown in Figure 1 . Variation between the highest and lowest pH value obtained at each volume of acid added over the three titrations on each antacid was less than 100/0 in all cases. The greatest variability occurred at the highest volumes of acid added. All antacids tested possessed significant buffering capacity however only "Eno" in one unit dose possessed a buffering capacity equivalent to sodium citrate 30 m!.
Hydrochloric acid IM 10 ml has been used in other studies as an approximation of the number of hydrogen ions contained in 100 ml gastric juice. 2 pH after titration with 10 ml acid has been used as an index of the extent to which an antacid might be expected to elevate the pH of 100 ml gastric juice. These data are presented in Table 2 . All antacids tested elevated pH above the postulated critical value of 2.5. 5 Note: The pH value after addition of \0 ml IM HCI is used to estimate the potential pH elevation produced by an antacid if mixed with 100 ml gastric juice. Values given are the average pHs over three tit rations for each antacid.
DISCUSSION
"Alka Seltzer Effervescent"2 and a soluble paracetamol preparation} are proprietary products which have been shown to possess satisfactory buffering capacities in vitro. Postulated advantages of proprietary antacids include increased palatability, reduced cost and longer shelf-life. )) Sodium bicarbonate solution 8.4% 20 ml is a non-particulate antacid alternative to sodium citrate which has been variably reported as effective 4 or ineffective 6 preoperatively in obstetric anaesthesia.
This brief pilot study confirms that proprietary antacid preparations have potentially useful buffering capacities and are cheaper than a sodium citrate preparation in clinical use. "Eno" possesses a buffering capacity equivalent to sodium citrate at one-seventh the cost using crude costing estimates. "Over the counter" prices were used as a simple consistent index of the relative costs of the antacid preparations. No significance is attached to the absolute cost of each preparation. Although hospital pharmacies may be able to produce sodium citrate more cheaply than the commercial formulation used in this study, these products may have a much shorter shelf-life than the commercial product thus potentially incurring more wastage.
The manufacturer's stated single dose (one sachet or one teaspoon) was used as the proprietary antacid dose as it was anticipated that this would represent the most conveniently selected and administered dose in the clinical situation. With the appropriate dose manipulation it is anticipated that all antacids tested would possess buffering capacities equivalent to sodium citrate.
For institutions with a high antacid usage, switching from sodium citrate solution to a proprietary antacid may offer a cost-effective alternative. However, any change from the well established sodium citrate to a different preparation should be preceded by determinations of in vitro and in vivo efficacy and laboratory testing for potential pulmonary toxicity. Since proprietary preparations may be effervescent, additional consideration should be given to the potential for patient harm resulting from carbon dioxide generation within the stomach.) Recommended clinical practice is to administer effervescent antacids only after effervescence has fully subsided in order to minimise this effect.
It is concluded from this brief study that some proprietary antacids may potentially offer a cost-effective alternative to sodium citrate preparations, but that acid neutralising abilities are variable between different proprietary antacids.
